Related Experiment Video

Updated: Jun 20, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Cytotoxic compounds in the treatment of castration-resistant prostate cancer

Patrick Lee1, Jeanny B Aragon-Ching

  • 1Division of Hematology and Oncology, George Washington University Medical Center, Washington, DC 20037, USA.

Anti-Cancer Agents in Medicinal Chemistry
|September 2, 2009
PubMed

Insights

New chemotherapy drugs are needed for prostate cancer that no longer responds to docetaxel. This review examines novel cytotoxic compounds, including platinums and microtubule agents, in clinical trials for advanced prostate cancer.

Area of Science:

  • Oncology
  • Urology
  • Medical Chemistry

Background:

  • Prostate cancer is a leading cancer in US men, often diagnosed early.
  • Metastatic castration-resistant prostate cancer (mCRPC) develops in a significant number of patients.
  • Docetaxel improves survival in mCRPC, but resistance is nearly universal.

Purpose of the Study:

  • To review novel cytotoxic agents for advanced prostate cancer.
  • To identify new therapeutic options beyond taxane resistance.
  • To focus on compounds in clinical investigation for mCRPC.

Main Methods:

  • Literature review of clinical investigations.
  • Focus on cytotoxic compounds in combination therapy.
  • Examination of novel agents like platinums and microtubule-targeting drugs.

Main Results:

  • Taxane therapy is effective but limited by resistance.
  • Second-line treatment options for mCRPC are scarce.
  • Several novel compounds are under active clinical investigation.

Conclusions:

  • There is a critical need for new chemotherapeutic agents in prostate cancer.
  • Novel compounds, including platinums and microtubule agents, show promise.
  • Ongoing clinical trials are evaluating these agents in various settings.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.